1. Leveraging Government support and global partnerships to increase biologics manufacturing capacity

2. What is BPA’s mission? fill key national capability gap in biologics development deliver key element to Smart State 10 year biotech strategy devise business model raise funds to support the model identify commercial partner design and build facility to commercial partner’s specs

3. The capability gap Leveraging Government support and global partnerships to increase biologics manufacturing capacity

4. The Business Model partner with Contract Manufacturing Organisation (CMO) public funded capital infrastructure : industry attraction design and build to CMO’s user requirement landlord-tenant relationship CMO has full autonomy in commercial operation BPA has transitional support function for 2-3 years Leveraging Government support and global partnerships to increase biologics manufacturing capacity

5. Q - Why a CMO model? A - a clear market trend over 5+ yrs Time-to-market pressure Offset risk – test the market first Spare capital during clinical development Allow developers to focus on areas of strength IP generation Clinical trials Marketing and distribution Leveraging Government support and global partnerships to increase biologics manufacturing capacity

6. BPA’s partnering methodology develop value proposition leverage complementary clinical development providers invite expressions of interest from CMO’S worldwide request for proposals from selected group evaluation of bids against set criteria offer Terms Sheet to DSM Biologics Leveraging Government support and global partnerships to increase biologics manufacturing capacity

7. Strategic investment in biopharmaceutical manufacturing – a Queensland case study Why DSM Biologics? Track record Financial stability Commercial focus No product IP – 100% customer service focus Technology and commercial differentiators

8. Quick history Dec 2009 - BPA signs Terms Sheet with DSM Biologics 2010 - concept design underway; negotiation of lease 2010 - building shell underway 2011 - completion of facility design and tender package Jan 2012 - internal fit out underway Snapshot of the future 2012 - complete fit out; procure process equipment Jan 2013 - commissioning and qualification Operations commence – July 2013 Leveraging Government support and global partnerships to increase biologics manufacturing capacity

10. Leverage other service providers: AIBN key linkage